SCHEMBL1339005

SCHEMBL1339005

CC(=O)c1ccc2c(c1)c1cc(-c3ccc(Cl)cc3)c(=O)n(C)c1n2C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
GABRA1 P14867 3/20 0.41
GABRG2 P18507 1/20 0.41
GABRB3 P28472 1/20 0.41
GABRA5 P31644 1/20 0.41
CNR1 P21554 9/20 0.41
CNR2 P34972 8/20 0.41
TACR1 P25103 1/20 0.39
ADRA2C P18825 2/20 0.38
SLC6A3 Q01959 2/20 0.38
EGFR P00533 1/20 0.38
ALOX5 P09917 1/20 0.38
ADORA3 P0DMS8 1/20 0.38
MAPK3 P27361 1/20 0.38
OPRL1 P41146 1/20 0.38
SLC18A2 Q05940 1/20 0.38
MAPK14 Q16539 1/20 0.38
TMEM97 Q5BJF2 1/20 0.38
SIGMAR1 Q99720 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1339208 0.88 KDM4E (0.42) ALDH1A1SMN1; SMN2SLC6A3HTR2AKDM4E
SCHEMBL1338146 0.88 MEN1 (0.39) ALDH1A1SMN1; SMN2GABRA1GABRG2GABRB3
SCHEMBL1337044 0.87 CXCR3 (0.39) SMN1; SMN2GABRA1GABRG2GABRB3GABRA5
SCHEMBL1338158 0.86 GSK3B (0.43) SMN1; SMN2GABRA1GABRG2GABRB3GABRA5
SCHEMBL1336873 0.86 GABRA1 (0.42) ALDH1A1GABRA1GABRG2GABRB3GABRA5
SCHEMBL1338500 0.84 CNR1 (0.36) ALDH1A1SMN1; SMN2GABRA1GABRG2GABRB3
SCHEMBL1338499 0.84 CNR1 (0.36) ALDH1A1SMN1; SMN2GABRA1GABRG2GABRB3
SCHEMBL1338688 0.84 GABRA1 (0.41) GABRA1GABRG2GABRB3GABRA5CNR1
SCHEMBL1338900 0.83 MAPT (0.49) ALDH1A1SMN1; SMN2MAPT
SCHEMBL1338903 0.83 MAPT (0.49) ALDH1A1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063061-B2 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites SANOFI-AVENTIS (FR) 2011-11-22 US disclosed
EP-1940840-B1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-07-21 EP disclosed
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 US disclosed
EP-1940840-A1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2008-07-09 EP disclosed
WO-2007045758-A1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof CYP11B2, CYP11B1, CYP2D6 ALDH1A1 283/4885SMN1; SMN2 3153/4885GABRA1 1457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.